DMAC

Company Overview — What Does DiaMedica Therapeutics Inc. Do?

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota. DiaMedica Therapeutics Inc. (DMAC) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Rick J. Pauls and employs approximately 20 people. With a market capitalization of $345M, DMAC is one of the notable companies in the Healthcare sector.

DiaMedica Therapeutics Inc. (DMAC) Stock Rating — Reduce (April 2026)

As of April 2026, DiaMedica Therapeutics Inc. receives a Reduce rating with a composite score of 34.3/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.DMAC ranks #3,393 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, DiaMedica Therapeutics Inc. ranks #517 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

DMAC Stock Price and 52-Week Range

DiaMedica Therapeutics Inc. (DMAC) currently trades at $5.88. The stock lost $0.30 (4.9%) in the most recent trading session. The 52-week high for DMAC is $10.42, which means the stock is currently trading -43.6% from its annual peak. The 52-week low is $3.19, putting the stock 84.3% above its annual trough. Recent trading volume was 373K shares, suggesting relatively thin trading activity.

Is DMAC Overvalued or Undervalued? — Valuation Analysis

DiaMedica Therapeutics Inc. (DMAC) carries a value factor score of 24/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 6.29x, versus the sector average of 2.75x.

At current multiples, DiaMedica Therapeutics Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

DiaMedica Therapeutics Inc. Profitability — ROE, Margins, and Quality Score

DiaMedica Therapeutics Inc. (DMAC) earns a quality factor score of 24/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -54.0%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -49.4% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

DMAC Debt, Balance Sheet, and Financial Health

DiaMedica Therapeutics Inc. has a debt-to-equity ratio of 9.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 11.81x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $3M.

DMAC has a beta of 1.43, meaning it is more volatile than the broader market — a $10,000 investment in DMAC would be expected to move 43.0% more than the S&P 500 on any given day. The stability factor score for DiaMedica Therapeutics Inc. is 36/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

DiaMedica Therapeutics Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, DiaMedica Therapeutics Inc. reported revenue of $0 and earnings per share (EPS) of $-0.70. Net income for the quarter was $-30M. Operating income came in at $-32M.

In FY 2025, DiaMedica Therapeutics Inc. reported revenue of $0 and earnings per share (EPS) of $-0.70. Net income for the quarter was $-33M. Operating income came in at $-34M.

In Q3 2025, DiaMedica Therapeutics Inc. reported revenue of N/A and earnings per share (EPS) of $-0.17. Net income for the quarter was $-9M. Operating income came in at $-9M.

In Q2 2025, DiaMedica Therapeutics Inc. reported revenue of N/A and earnings per share (EPS) of $-0.18. Net income for the quarter was $-8M. Operating income came in at $-8M.

Over the past 8 quarters, DiaMedica Therapeutics Inc. has reported varying levels of revenue. Investors analyzing DMAC stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

DMAC Dividend Yield and Income Analysis

DiaMedica Therapeutics Inc. (DMAC) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

DMAC Momentum and Technical Analysis Profile

DiaMedica Therapeutics Inc. (DMAC) has a momentum factor score of 50/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 49/100 reflects moderate short selling activity.

DMAC vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, DiaMedica Therapeutics Inc. (DMAC) ranks #517 out of 838 stocks based on the Blank Capital composite score. This places DMAC in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing DMAC against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full DMAC vs S&P 500 (SPY) comparison to assess how DiaMedica Therapeutics Inc. stacks up against the broader market across all factor dimensions.

DMAC Next Earnings Date

No upcoming earnings date has been announced for DiaMedica Therapeutics Inc. (DMAC) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy DMAC? — Investment Thesis Summary

The quantitative profile for DiaMedica Therapeutics Inc. suggests caution. The quality score of 24/100 flags below-average profitability. The value score of 24/100 indicates premium valuation. High volatility (stability score 36/100) increases portfolio risk.

In summary, DiaMedica Therapeutics Inc. (DMAC) earns a Reduce rating with a composite score of 34.3/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on DMAC stock.

Related Resources for DMAC Investors

Explore more research and tools: DMAC vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare DMAC head-to-head with peers: DMAC vs AZN, DMAC vs SLGL, DMAC vs VMD.